Targeted binding agents against B7-H1
US9493565B2 · kind B2 · utility
15Cited by
2References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 6, 2014 |
| Grant date | Nov 15, 2016 |
| Priority date | — |
| Expiry date | Dec 10, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.